Isis Pharmaceuticals announced data from a Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx experienced reductions of up to 70% in apolipoprotein C-III and up to 64% in triglycerides. In addition, patients treated with ISIS-APOCIIIRx experienced an up to 52% increase in high-density lipoprotein cholesterol, the 'good' cholesterol, and an up to 77% reduction in apoC-III-associated very low-density lipoprotein particles. Isis is also evaluating ISIS-APOCIIIRx in this Phase 2 study as a monotherapy in patients with severely high triglycerides and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.
- Health Care Industry
- Isis Pharmaceuticals